Personally I believe that big Pharma spends much of their
Personally I believe that big Pharma spends much of their time and money defending and extending their patents on blockbuster products, and little in developing new dramatically different technologies and drugs. They step in when tiny biotech or research organizations have developed great new products and either partner them, or buy the companies.
Probably the biggest reasons most tiny biotech's can't bring products to approval is the cost of Phase 3 trials, but this may change if Gottlieb is successful in changing the way the FDA does business. Small biotech's may be able to afford to take drugs to approval, and with contract facilities making the drugs may be able to provide sufficient quantity of the drug to meet demand without spending the hundreds of millions it costs for production facilities. I'm not suggesting they won't need big Pharma at all, but if they take drugs to, or near approval, they can partner on far better terms as they need big Pharma for distribution around the world, though they may keep the U.S. to themselves. I think it's time that a more equitable split of the sales revenue takes place, and that can happen if tiny biotech's can take drugs essentially to approval because the cost of doing so is dropping. As is, the developer of drugs rarely sees much over 10% of sales revenue, and frequently substantially less than that until a drug reaches blockbuster levels through a series of milestones based on sales goals.
Gary
OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
An Unusual Alliance with Far-Reaching Implications Every once in a while, a nonprofit steps up with a move that makes even the toughest investors take notice. This isn't some Wall Street ticker talk, sure, but it’s worth turning your chair toward the table. The Human Development Fund (HDF) has penned a strategic deal with the Islamic Development Bank (IsDB), putting its...
Continue Reading
Market Trends and Key Drivers Imagine riding a slow but steady bull market in insulation—sounds mundane, but the numbers don't lie. MarketsandMarkets™ had the scoop, predicting the Continuous Insulation Market will balloon from USD 56.98 billion in 2026 to USD 67.74 billion by 2031, putting down roots with a 3.5% CAGR. Now, you and I both know that when real estate...
Continue Reading
Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...
Continue Reading
Tax Strategy: Not All About April 15 Ready to fend off that taxman? Well, don’t just wait for that dreaded April deadline. Greg Harrison over at Harrison Financial Management spills some wisdom on the oft-overlooked nuances between tax planning and tax preparation. It’s not just semantics; it’s the difference between shaping your financial future and simply...
Continue Reading
Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...
Continue Reading
In a world where bureaucratic red tape often chokes efficiency, Empyrean throws a lifeline to public sector bodies. They've nabbed a cooperative purchasing contract with OMNIA Partners, dialing down the procurement guts to make benefits administration easier for government and education folks. Streamlining Public Sector Procurement Public sector organizations ain't...
Continue Reading
A New Phase in Foam Blowing Agents You don’t come across a true leap in materials technology every day, and that’s exactly what's unfolding with Solstice Advanced Materials' latest venture. They’re not just talking the talk; they've hit a milestone in developing a next-gen foam blowing agent. This isn't just another tweak in a spreadsheet—it's a potential pivot in...
Continue Reading
Ridero Gets Serious About Fixing Auto Financing When you've got startups like Ridero stepping up with a $2.7 million cash infusion, you can't help but sit up and listen. These folks are charging head-on into the automotive financing jumble, and they're bringing some high-tech toys to the party. With RiverPark Ventures and a slew of other big-name backers, Ridero's dialing...
Continue Reading
Wuliangye Takes Center Stage at Global Event Everyone's chasing that global branding magic, but here's Wuliangye strutting its stuff at the Global Panda Partners Conference. Held in Sichuan Province from November 2 to 4, this is not just another show; it's a bold move from the Chinese baijiu maker to push the 'harmony and coexistence' mantra on the world stage. Not just...
Continue Reading
Skills Intelligence Takes Center Stage There's a fresh breeze blowing through the workforce planning domain, thanks to the newly expanded partnership between TalentNeuron and CodeSignal. They've strapped together their expertise to craft what's now touted as the most comprehensive skills intelligence available to organizations. A claim big enough to make us stop,...
Continue Reading
Top 5 Most Recently Viewed Articles
Telehealth Diagnostic Categories Show Remarkable Trends As the landscape of healthcare continues to evolve, recent data has highlighted the significant role of telehealth in diagnosing various conditions. Sleep disorders have emerged as one of the top five telehealth diagnostic categories reported nationwide, according to the latest statistics from FAIR Health's Monthly...
Continue Reading
Class Action Overview for DoubleVerify Holdings, Inc. In recent days, the spotlight has been shining on DoubleVerify Holdings, Inc. as investors navigate the complexities of a class action lawsuit. This legal battle has significant implications for those who purchased DoubleVerify stock within the defined class period. About DoubleVerify Holdings, Inc. DoubleVerify...
Continue Reading
Kvika Bank's Share Buyback Program Update Recently, Kvika banki hf. announced significant developments related to its share buyback program. In week 10, the bank acquired 16,147,962 of its own shares, amounting to a total expenditure of 322,656,231 ISK. The details of these transactions are outlined below: Details of Share Purchases The bank executed several transactions...
Continue Reading
ZimVie Enters Acquisition Agreement with ARCHIMED ZimVie Inc., a prominent player in the dental implant sector, has entered a definitive agreement to be acquired by ARCHIMED, a healthcare-focused investment firm. Under the deal, stockholders of ZimVie will receive $19.00 per share, representing a substantial premium over recent trading averages, which stands at...
Continue Reading
CEO Ryan Melsert's Vision for a Sustainable Future American Battery Technology Company (NASDAQ: ABAT) is at the forefront of critical battery mineral manufacturing, as highlighted by CEO Ryan Melsert's recent keynote address at the global Round Table on Sustainable Development. This event brought together leaders in energy and mining sectors to discuss pressing...
Continue Reading